Revenue Update on Luminex Corporation(NASDAQ:LMNX)

Luminex Corporation(NASDAQ:LMNX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $64.17M. Analysts estimated a revenue of $61.20M. Earnings per share were $0.33. Analysts had estimated an EPS of $0.15.

Luminex Corporation (LMNX) made into the market gainers list on Thursdays trading session with the shares advancing 2.19% or 0.47 points. Due to strong positive momentum, the stock ended at $21.9, which is also near the day’s high of $21.95. The stock began the session at $21.38 and the volume stood at 3,25,344 shares. The 52-week high of the shares is $23.75 and the 52 week low is $16.16. The company has a current market capitalization of $954 M and it has 4,35,48,956 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jan 6, 2016, G Walter Ii Loewenbaum (director) sold 41,056 shares at $20.53 per share price.Also, On Dec 18, 2015, Russell W Bradley (SVP, Corp Dev & CMO) sold 6,514 shares at $22.75 per share price.On May 29, 2015, Nachum Shamir (CEO) purchased 6,000 shares at $16.73 per share price, according to the Form-4 filing with the securities and exchange commission.

Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Company’s xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Company’s xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Company’s products include Instruments Consumables Software and Assay Product Families.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Luminex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Luminex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.